RxDoctor Payments Data

Julia Stoerr, PA

Physician Assistant · Orchard Park, NYNPI 1265982219

Payments from drug & device makers

$9,990in general payments, 2019–2025

Across 443 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • AbbVie$1K
  • SK Life Science, Inc.$1K
  • Jazz Pharmaceuticals Inc.$947
  • UCB, Inc.$804
  • Collegium Pharmaceutical, Inc.$664
  • plus $4K from 46 others

What the payments were for

  • Travel & lodging$95210%
  • Food & beverage$8,81788%
  • Education$2212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,990 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$28,333
Medicare patients
170
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)60$248,806
FycompaPerampanel84$105,713
BriviactBrivaracetam37$79,350
XcopriCenobamate64$70,806
AptiomEslicarbazepine Acetate28$66,294
Lamictal XrLamotrigine13$52,918
LamictalLamotrigine23$41,632
QuliptaAtogepant32$38,446
KeppraLevetiracetam27$35,865
NayzilamMidazolam17$28,411
Levetiracetam567$27,842
ZonegranZonisamide14$23,661
Nurtec OdtRimegepant Sulfate18$22,861
Lamotrigine ErLamotrigine47$14,681
UbrelvyUbrogepant14$14,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$804$107,76054 claims
Eisai Inc.Fycompa$122$105,71384 claims
SK Life Science, Inc.Xcopri$1,121$70,80664 claims
AbbVieQulipta, Ubrelvy$1,368$53,02746 claims
PfizerNurtec Odt, Dilantin$161$27,31537 claims
Upsher-smith Laboratories LLCTopiramate$16$2,055101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →